LadhaniSNWhitePJCampbellH, et al.Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK. Lancet Infect Dis2024; 24: e576–e583.
2.
Petousis-HarrisHPaynterJMorganJ, et al.Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet2017; 390(10102): 1603–1610.
3.
NadarzynskiTFrostMMillerD, et al.Vaccine acceptability, uptake and completion amongst men who have sex with men: a systematic review, meta-analysis and theoretical framework. Vaccine2021; 39(27): 3565–3581.
4.
NadarzynskiTLlewellynCRichardsonD, et al.UK healthcare professionals’ uncertainties, barriers and facilitators to the introduction of targeted human papillomavirus vaccination for men who have sex with men. Sex Health2017; 14(4): 372–377.
5.
RichardsonDPickeringATrotmanD, et al.Pharyngeal gonorrhoea in men who have sex with men. Int J STD AIDS2021; 32(5): 449–452.
6.
RichardsonDTrotmanDDevlinJ, et al.Gonorrhoea proctitis in men who have sex with men: the importance of performing culture specimens for antimicrobial resistance surveillance. J Eur Acad Dermatol Venereol2021; 35(12): e873–e875.
7.
RaccagniARAlbertonFCastagnaA, et al.Vaccines against emerging sexually transmitted infections: current preventive tools and future perspectives. New Microbiol2022; 45(1): 9–27.
